December 20, 2023 01:14 PM EST
R&D
Pharma
FDA+

FDA en­cour­ages col­lab­o­ra­tion be­tween mon­o­clon­al an­ti­body spon­sors to keep pace with emerg­ing Covid vari­ants

Lia DeGroot

The FDA is en­cour­ag­ing de­vel­op­ers of Covid-19 mon­o­clon­al an­ti­bod­ies to col­lab­o­rate and bet­ter tar­get emerg­ing vari­ants in

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

FDA picks con­tro­ver­sial doc­tor Vinay Prasad as CBER di­rec­tor, in about-face from Marks

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times